Some people using Mounjaro in the UK may receive a redesigned KwikPen during 2026 as Eli Lilly introduces changes to its injection device. Despite the updated appearance and internal mechanism, the pen continues to deliver tirzepatide in the same prescribed strengths. The modification affects the device rather than the medication, with no intended change to its effectiveness.

The new Mounjaro KwikPen may look different before its first use and after all four scheduled injections. Although the dosing routine and administration method remain unchanged, the redesign has raised questions about the differences between the old and new pens, particularly the leftover liquid known as the ‘golden dose’. Understanding these changes can help patients recognise the updated device and use it correctly.

GLP-1 / GIP

Mounjaro

Dual-agonist support that helps curb appetite, hunger, and cravings to drive substantial, sustained weight loss.
  • ✔ ~22.5% average body weight loss
  • ✔ Significant weight reduction
  • ✔ Improves blood sugar levels
  • ✔ Clinically proven weight loss

Key Insights About the New Mounjaro Pen

  • Eli Lilly introduced a redesigned Mounjaro KwikPen in the UK in April 2026.
  • The updated plunger reduces leftover medication and makes the four-dose completion point clearer.
  • Both pen versions contain the same tirzepatide strengths and deliver four weekly injections.
  • The residual liquid, known as the ‘golden dose’, is not an approved fifth injection.
  • Injection techniques, storage requirements and disposal instructions remain unchanged.
  • Patients should follow the manufacturer’s instructions and seek professional advice if their pen appears faulty.

What’s Different About the 2026 Mounjaro KwikPen?

During 2026, Eli Lilly introduced an updated Mounjaro KwikPen design in the UK. The revised internal mechanism reduces visible residual medicine and helps patients recognise when the prescribed four-dose cycle is complete. The medication, available strengths and weekly administration schedule remain unchanged.

Redesigned Plunger Mechanism

The updated pen includes an additional internal component that extends the plunger’s movement through the cartridge. This allows more of the solution to be dispensed during the four prescribed injections while preserving sufficient liquid for priming. Less medication remains afterwards, making it harder to access the unofficial ‘golden dose’.

Lower Starting Liquid Level

Patients may notice that the plunger sits further forward in the new KwikPen, giving the impression that the cartridge contains less medication. This is an expected result of the redesign, not a filling defect. Each device still provides four measured 0.6 mL doses, alongside sufficient solution for the recommended priming steps.

Easier End-of-Pen Identification

Once the fourth weekly injection is complete, the plunger’s final position provides a clearer visual indication that the pen has reached the end of its intended use. Although a small amount of liquid may remain, it is not an additional authorised dose. The KwikPen should be discarded after four injections.

What Happens When Your Mounjaro KwikPen Is Empty?

Once you have administered the final prescribed injection, your Mounjaro KwikPen must be discarded, regardless of any remaining liquid. The updated design helps make this endpoint easier to recognise, reducing the likelihood of mistaking residual medication for another usable dose.

Four-Dose Treatment Cycle

A Mounjaro KwikPen delivers four individual injections of 0.6 mL, taken at weekly intervals. The cartridge also contains an extra solution to support priming and correct pen operation. This remaining liquid is not intended for another injection, and the device must not be used for a fifth dose.

Understanding the Golden Dose

The term ‘golden dose’ refers to the medication sometimes visible in older KwikPens after completing all four injections. Although it may appear usable, this leftover tirzepatide is not a calibrated or approved fifth dose. The revised plunger design reduces the remaining amount and makes accessing it more difficult.

Dangers of Using Leftover Medicine

Attempting to remove residual medication with a separate syringe or manipulating the pen can lead to incorrect dosing, contamination and device damage. These practices may compromise treatment safety. Never force the mechanism, dismantle the pen or attempt to extract an additional injection from a used KwikPen.

Disposing of Your Used Pen

Detach the needle and place it immediately in an approved sharps container. Follow your local pharmacy or council’s instructions for disposing of the needle-free pen. Discard the KwikPen after four doses or 30 days from its first use, whichever comes first, even if liquid remains. For additional guidance, read our Mounjaro storage advice.

Mounjaro

  • check Clinician-led medical assessment
  • check Personalised dosing and nutrition support
  • check Ongoing clinical monitoring throughout treatment
Check Eligibility
CTA Image

How to Recognise the Updated Mounjaro KwikPen

The new Mounjaro KwikPen can be identified by changes to its internal plunger, which is visible through the cartridge window. The redesigned component appears thicker and begins further forward than in the previous version. However, the outer packaging and colour-coded dose labels remain largely unchanged.

The table below highlights the main differences between the two designs.

Feature Previous Mounjaro KwikPen Updated Mounjaro KwikPen
Internal plunger Conventional, smaller component Longer, more prominent component
Starting position Positioned nearer the cartridge’s base Sits further forward before first use
Leftover medication More liquid visible after four doses Reduced residual liquid
Packaging Established colour-coded design Similar packaging and dose labelling

During the UK rollout, patients may receive either version depending on available pharmacy stock. Both pens contain four prescribed weekly doses and use the same injection procedure. If you cannot identify your device, check the illustrations in the accompanying patient instructions or ask your pharmacist for guidance.

What Stays the Same in the Updated Mounjaro KwikPen?

The new Mounjaro KwikPen has a modified internal design, but the medicine, dosing schedule and administration process remain unchanged. Patients can continue using their prescribed treatment as usual, regardless of which pen version they receive.

Medication and Dose Strengths

Both KwikPen versions contain tirzepatide in the same six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. Each device provides four measured 0.6 mL injections, administered once weekly, without changes to the prescribed dose or treatment effectiveness.

Injection and Storage Instructions

The existing steps for priming, selecting the dose and injecting under the skin remain the same. Unopened pens require refrigeration at 2°C–8°C, while pens in use can be stored below 30°C for up to 30 days after their first injection.

Product Identification and Disposal

GTIN and PIP codes remain unchanged, so the redesign does not affect prescribing or pharmacy ordering procedures. Both KwikPen versions also follow the same disposal requirements, with no additional steps introduced by the updated design.

For further guidance on the redesigned Mounjaro KwikPen or your current treatment, an online consultation with a qualified UK healthcare professional can help clarify device instructions, address medication concerns and support safe, effective weight management.

Why Did Eli Lilly Redesign the Mounjaro KwikPen?

Eli Lilly revised the Mounjaro KwikPen to help patients identify when all four prescribed doses have been used. The updated mechanism leaves less visible medication in the cartridge, reducing confusion about whether the pen contains another usable injection.

The redesign also aims to discourage attempts to extract the leftover liquid, commonly called the ‘golden dose’, which is not an approved fifth injection. By making the end of the four-dose cycle more apparent, the new pen supports clearer and safer use of Mounjaro in the UK.

Conclusion: Understanding the Updated Mounjaro KwikPen

The updated Mounjaro KwikPen introduces internal design improvements while preserving the prescribed treatment and administration process. Understanding these changes can help patients recognise their device, follow the manufacturer’s instructions and avoid unsafe attempts to access medication remaining after the final injection.

Both KwikPen versions deliver the same prescribed treatment, so the redesign does not require changes to your medication routine. Mayfair Weight Loss Clinic offers medically supervised weight-management support, helping patients understand their Mounjaro treatment, follow safe injection practices and make informed decisions about their ongoing care.

FAQs About the New Mounjaro Pen

Can you still use the old Mounjaro KwikPen in 2026?

Yes, the original Mounjaro KwikPen can still be used if it was supplied by a legitimate pharmacy, remains within its expiry date and is stored correctly. The introduction of the redesigned device does not automatically make older genuine pens unsuitable for use.

Does the new Mounjaro pen cause more pain?

There is no established evidence that the redesigned KwikPen causes more injection pain. Discomfort may depend on needle placement, injection technique and individual sensitivity. Contact your healthcare professional if you experience persistent pain or unusual injection-site reactions.

Can you use the same needles with the new Mounjaro pen?

The updated device continues to require KwikPen-compatible needles. Always attach a new sterile needle for each injection. If you are unsure whether your existing needles are compatible, ask your pharmacist before using them.

What should you do if your Mounjaro pen stops working?

Do not force the dose knob or attempt to repair a faulty KwikPen. Check the manufacturer’s instructions and contact your pharmacist or prescriber if the problem continues. Suspected device defects can also be reported through the UK’s MHRA Yellow Card scheme.

Can you change your Mounjaro injection day?

Yes, you can change your weekly injection day, provided at least 72 hours have passed since your previous dose. Continue administering your prescribed injection once weekly on the newly selected day, following the UK patient leaflet.

What do the lines on the Mounjaro pen cartridge mean?

The markings visible on the KwikPen cartridge are part of the device design. They do not indicate how many doses remain or how much medicine should be injected. Follow the dose window and manufacturer’s instructions rather than using cartridge markings to estimate doses.

What if the liquid in your Mounjaro pen looks cloudy?

Mounjaro solution should appear clear and colourless to slightly yellow. Do not use the pen if the liquid is cloudy, contains particles or appears unusually discoloured. Contact your pharmacist for advice and avoid injecting medication that may be unsuitable for use.

How can you check whether your Mounjaro pen is genuine?

Obtain Mounjaro only from registered UK pharmacies following a valid prescription. Check the packaging, dose label, batch number and expiry date. If anything appears suspicious, do not use the pen. Contact your pharmacist and report suspected counterfeit medication to the MHRA.

GLP-1 / GIP

Mounjaro

Dual-agonist support that helps curb appetite, hunger, and cravings to drive substantial, sustained weight loss.
  • ✔ ~22.5% average body weight loss
  • ✔ Significant weight reduction
  • ✔ Improves blood sugar levels
  • ✔ Clinically proven weight loss
GLP-1

Wegovy

A weekly GLP-1 treatment proven to reduce hunger and support meaningful, long-term fat loss.
  • ✔ ~16.9% average body weight loss
  • ✔ Boosts metabolic & cardiovascular health
  • ✔ Proven, long-established safety profile
  • ✔ Weekly injection, easy to use